Superficial Radiation Therapy (SRT) for Basal Cell Carcinoma

Superficial radiation therapy, commonly called SRT, is a non-surgical treatment for basal cell carcinoma that uses low-energy X-rays to destroy cancer cells in the skin without cutting. Cure rates in recent studies range from about 97% to over 99%, depending on how patients are selected and whether image guidance is used during treatment. SRT has gained traction over the past decade as a genuine alternative to surgery, particularly for patients who cannot or prefer not to undergo excision, but the debate over how it stacks up against Mohs surgery remains lively and, at times, contentious.

How SRT Works

SRT delivers X-rays at energies typically between 50 and 100 kilovolts, which is far lower than what conventional radiation oncology machines produce. At those energies, the radiation penetrates only a few millimeters into the skin, depositing its dose in the superficial tissue layers where basal cell carcinomas grow. The cancer cells absorb that energy and sustain enough DNA damage that they can no longer divide and eventually die off. Because the beam doesn’t reach deep structures like muscle or bone, the treatment spares underlying tissue in a way that deeper radiation cannot.

A typical course involves multiple treatment sessions, often spread over several weeks. During each visit, a cone-shaped applicator is placed against the skin over the tumor, and the machine delivers a measured dose of radiation for a few minutes. The whole appointment is usually quick, requires no anesthesia, and leaves no surgical wound. You walk in, sit or lie still for the treatment, and walk out.

Cure Rates and What Drives Them

The numbers you see quoted for SRT cure rates vary, and the reason is worth understanding: patient selection and follow-up length change the picture dramatically. A large study tracking image-guided SRT found freedom-from-recurrence rates of about 99.7% at two years and 99.5% at four and six years, with no significant difference based on tumor location or the patient’s sex.¹ A separate long-term follow-up of carefully selected patients reported a raw recurrence rate of just 1.6%, translating to cure rates around 98%.²

Those results look excellent, but an older study paints a more sobering picture: when SRT was used more broadly, the estimated five-year recurrence rate for all basal cell carcinomas was around 16%. Recurrence varied by subtype, with nodular BCC faring best at about 8% recurrence, while the sclerosing subtype recurred in roughly 28% of cases.³ That gap between older and newer data reflects real advances in how the treatment is delivered, particularly the addition of imaging, but also a shift toward treating tumors that are better suited to radiation in the first place.

Most recurrences after SRT appear within the first three years, so long follow-up matters when evaluating cure claims. A study reporting 99% success at one year tells you less than one reporting 98% at five years.

The Mohs Surgery Comparison

Mohs micrographic surgery has long been considered the gold standard for non-melanoma skin cancer, and any conversation about SRT inevitably involves a head-to-head comparison. The evidence here is genuinely mixed, and the disagreement between studies is striking enough that both sides have ammunition.

One pooled analysis found that image-guided SRT had a statistically better two-year recurrence probability than Mohs for both basal and squamous cell carcinomas.⁴ However, a systematic review and meta-analysis that cast a wider net came to the opposite conclusion: local recurrence rates were lower for Mohs at about 1.9% compared with roughly 6.3% for SRT.⁵

How can two analyses land on different sides? The studies they pulled from differed in the type of SRT used (image-guided versus conventional), the patient populations, the tumor characteristics, and the length of follow-up. Image-guided SRT, which is a newer technique, tends to produce better results than older SRT protocols, and analyses that lump all SRT eras together will arrive at higher recurrence numbers. A network meta-analysis that included external-beam radiation alongside other treatments estimated radiation’s recurrence rate at about 3.5%, which was similar to the rates for standard surgical excision and Mohs.⁶

The honest reading of the current evidence is that Mohs surgery still has the longest and most consistent track record, while modern image-guided SRT appears to be closing the gap. Whether SRT has genuinely caught up or simply looks better in more recently treated cohorts is a question that only longer follow-up and more head-to-head trials can settle.

What Image Guidance Actually Adds

Much of the improvement in SRT outcomes over the past decade comes from pairing the radiation with high-resolution dermal ultrasound. This imaging technology, operating at around 22 megahertz, lets the treating clinician see the tumor’s shape and depth before, during, and after the treatment course.⁷ In practical terms, the clinician can confirm the tumor’s margins before each fraction, adjust if the tumor is shrinking or shifting, and verify at the end that the lesion has responded.

Without imaging, SRT relies on clinical measurements, essentially what the doctor can see and feel on the surface. That works reasonably well for flat, well-defined lesions but becomes less reliable when a tumor has irregular borders or extends deeper than expected. Image-guided SRT, or IGSRT, adds a layer of precision that older SRT protocols lacked and likely explains why the recurrence numbers from IGSRT-era studies look so different from those published twenty or thirty years ago.

Who Is a Good Candidate

SRT does not replace surgery for everyone. It occupies a particular niche, and understanding that niche helps you have a more productive conversation with your dermatologist. Published guidelines and clinical data identify several scenarios where SRT makes the most sense:

Surgical risk: Patients on blood thinners, those with poorly controlled diabetes, or anyone with conditions that impair wound healing may face complications from excision. SRT avoids the wound entirely.⁸
Cosmetically sensitive areas: Tumors on the nose, ears, or eyelids can leave noticeable scars after surgery. SRT avoids tissue removal, which can matter when function or appearance is at stake.
Lower extremity tumors: Surgical wounds on the legs, particularly in elderly patients, heal slowly and are prone to complications. A study specifically focused on lower-extremity basal and squamous cell carcinomas treated with SRT reported a 97.4% cure rate.⁹
Patient preference: Some patients simply prefer to avoid surgery. That preference is treated as a legitimate indication in the dermatology literature, not a second-class reason.

Conversely, very deep tumors, lesions with perineural invasion, or cancers that have already recurred multiple times after prior treatments are situations where most clinicians would steer toward surgery, particularly Mohs, rather than radiation.

Aggressive Subtypes and High-Risk Tumors

One persistent concern about SRT has been whether it can handle the more aggressive forms of basal cell carcinoma. Sclerosing, infiltrative, morpheaform, and micronodular subtypes grow in patterns that make them harder to treat by any method. The older study mentioned earlier found that sclerosing BCC had a recurrence rate nearly three and a half times higher than the nodular subtype after SRT.¹⁰

Newer data from image-guided SRT, however, challenges that pessimism. A large analysis of nearly 8,000 BCC lesions treated with IGSRT found no recurrences in the high-risk subtype group, with local control rates of 100% at both two and five years. Those rates were statistically similar to the non-high-risk group, which achieved control rates above 99%.¹¹ That study is a preprint and awaits full peer review, so its conclusions should be held with a degree of caution. But the direction of the findings suggests that image guidance may have substantially improved SRT’s ability to handle aggressive subtypes that previously had poor outcomes with radiation.

Side Effects During and After Treatment

SRT’s appeal is partly that its side effects tend to be manageable compared with surgery, but “manageable” does not mean absent. Skin reactions are nearly universal with any form of radiation therapy, reported in up to 95% of patients receiving RT of any kind.¹² With SRT specifically, the reactions are localized to the treatment site and classified by timing and severity.

Acute reactions, meaning those that develop during treatment or within a few weeks after, typically include redness, dryness, peeling, and sometimes a moist, raw patch similar to a bad sunburn. In the outpatient IGSRT experience, about 95% of lesions with toxicity scoring received low-grade scores, while roughly 5% developed more significant reactions graded as moderate to severe. These changes vary in severity, course, and prognosis from person to person.¹³

Long-term changes at the treatment site are more subtle but worth knowing about. After the acute reaction heals, the treated skin may show thinning, lighter pigmentation, and visible small blood vessels called telangiectasia. The loss of a healthy reddish complexion in the treated area is also common.¹⁴ These changes tend to be permanent but mild enough that most patients find them cosmetically acceptable, particularly compared with a surgical scar. On darker skin tones, hypopigmentation can be more noticeable and is worth discussing with your provider beforehand.

How SRT Compares with Non-Surgical Alternatives

If you are exploring non-surgical options, SRT is not the only one, but it consistently outperforms most of the others. A network meta-analysis comparing multiple treatments for primary basal cell carcinoma found that cryotherapy, topical 5-fluorouracil, imiquimod cream, and photodynamic therapy all had significantly higher recurrence rates than radiation, surgery, or Mohs. Cryotherapy recurred in roughly 22% of cases, imiquimod in about 14%, and photodynamic therapy in 17% to 19%, compared with about 3.5% for external-beam radiation and 3.8% for both excision and Mohs.¹⁵

The takeaway is that if surgery is off the table for medical or personal reasons, SRT is the non-surgical option with the strongest efficacy evidence. Topical treatments and cryotherapy can work well for very superficial, low-risk lesions, but their recurrence rates are substantially higher across the board.

What Happens If BCC Recurs After Radiation

Recurrence after SRT is uncommon, but when it does happen, the resulting situation is more complex than a typical recurrent skin cancer. Irradiated tissue heals differently, scars unpredictably, and can obscure tumor margins. Basal cell carcinoma that recurs after radiation therapy has been described as deserving its own subclassification among recurrent BCCs because it is particularly difficult to eradicate. Standard surgical excision or additional radiation tend to have high failure rates in this setting.¹⁶

Mohs surgery is generally considered the best salvage option because it examines 100% of the surgical margin under a microscope, mapping out tumor extensions that are invisible to the naked eye in irradiated skin. A retrospective study of recurrent BCCs treated with radiation did find reasonable outcomes overall, suggesting that repeat radiation can work in some cases.¹⁷ But the general consensus favors Mohs for post-radiation recurrences when surgery is feasible. This is one reason many guidelines still recommend surgery as the first-line treatment for tumors in high-risk locations: if the first treatment fails, you want the widest range of salvage options available.

The Treatment Experience in Practice

From the patient’s perspective, SRT involves multiple office visits over the span of several weeks. A common schedule runs two to three sessions per week for roughly three to five weeks, though protocols vary. Each session lasts only a few minutes of actual radiation delivery, though the appointment may be longer to account for setup, imaging, and skin checks.

There is no anesthesia, no incision, and no stitches. You do not need someone to drive you home. Most people continue their normal activities throughout the treatment course, which is a meaningful practical advantage over surgery, particularly for patients with mobility issues or those who live alone. The treated area is kept clean and moisturized between visits, similar to caring for a mild burn.

Adherence to the full course of treatment matters. Cutting sessions short or skipping appointments reduces the total radiation dose and can leave viable cancer cells behind. If the logistics of multiple visits over several weeks feel unmanageable, that is worth discussing with your provider early, since surgery is a single-visit procedure for most basal cell carcinomas.

Combination Therapy for Advanced Basal Cell Carcinoma

Most basal cell carcinomas are caught early and treated with a single modality, but a small fraction grow large enough to become locally advanced and unresectable. For those cases, researchers have begun combining radiation with hedgehog pathway inhibitors like vismodegib, a targeted drug that blocks the signaling pathway driving BCC growth. A phase II trial of vismodegib combined with curative-intent radiation in patients with unresectable locally advanced BCC found high rates of local control and durable improvements in quality of life.¹⁸

A case series exploring hedgehog inhibitor induction followed by superficial radiation therapy reported that all twelve patients achieved an initial complete response. At a median follow-up of 45 months, roughly 89% of patients remained progression-free, though two experienced eventual relapse.¹⁹ These combination approaches are still being studied and are not standard care for typical BCCs. They represent a frontier for the small subset of tumors that have grown beyond what either surgery or radiation alone can handle.

SRT, Medicare, and Access Questions

SRT devices are increasingly found in dermatology offices rather than hospital-based radiation oncology departments. This shift has made the treatment more accessible for patients who would otherwise need referral to a separate facility, especially in areas without a nearby radiation center. The equipment is compact enough to fit in a standard clinic room, and the low-energy X-rays require far less shielding than conventional radiation therapy machines.

The growing adoption of image-guided SRT has raised questions about cost. Adding dermal ultrasound imaging to each treatment session increases the per-session billing compared with non-image-guided SRT. Whether that added cost is justified by meaningfully better outcomes is an active discussion in the dermatology and health policy literature. For patients covered by Medicare, SRT is generally a covered procedure, but the specifics of coverage for image guidance can vary. If cost is a concern, ask your provider’s billing office about anticipated out-of-pocket expenses before starting a treatment course.

From a radiation safety standpoint, the low energies used in SRT mean that shielding requirements are modest. The clinician may step behind a barrier or leave the room during the brief treatment delivery, but the walls of a standard office can often provide adequate protection. This is a far cry from the heavily shielded vaults needed for high-energy radiation equipment, which is part of why SRT has been practical to deploy in outpatient dermatology clinics.